Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CITY-TFR2
- Development stage
- Preclinical
- Lead developer
- City Therapeutics
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Subcutaneous
01
Overview
CITY-TFR2 is a preclinical GalNAc-conjugated small interfering RNA (siRNA) therapeutic candidate designed to target transferrin receptor 2 (TFR2) in the liver. Developed by City Therapeutics, the drug utilizes RNA interference (RNAi) to silence hepatic TFR2 expression, which in turn lowers hepcidin levels and restores iron availability for red blood cell production. It is being developed for the treatment of anemia of chronic disease, with an initial focus on anemia associated with myelofibrosis, and potential expansion into anemia of chronic kidney disease and chronic inflammatory conditions such as inflammatory bowel disease.
02
Targets
TFR2 (Transferrin receptor 2)
Beyond the preview
Go deeper on CITY-TFR2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CITY-TFR2.